Business Wire

ICR Acquires Consilium Strategic Communications, Creating Global Leader in Healthcare Communications and Investor Relations

12.9.2023 14:50:00 EEST | Business Wire | Press release

Share

ICR, a leading global strategic communications and advisory firm, today announced it has acquired Consilium Strategic Communications, a leading international strategic healthcare communications and investor relations firm focused on Europe and headquartered in London. The transaction, which follows almost a decade of joint venture collaboration, will combine Consilium with ICR’s US-based healthcare practice, ICR Westwicke, forming a global healthcare strategic and financial communications powerhouse with nearly 200 clients and more than 100 team members across three continents.

Current clients of Consilium will immediately benefit from the full breadth of ICR’s services including: investor relations; capital markets and IPO advisory; investor access; ESG advisory; corporate communications and media relations; crisis and special situations; marketing PR; social media; and branding & design. Consilium will operate under the “ICR Consilium” brand and integrate its teams and activities with ICR’s existing healthcare practice.

Consilium was formed in 2013 by Mary-Jane Elliott, Founder and Managing Partner, along with Amber Fennell, Senior Partner and Co-founder. Over the past 10 years the firm has grown to become the market leader in healthcare strategic communications and IR in Europe. Mary-Jane Elliott will continue to lead the firm from its headquarters in London and both she and Amber Fennell will join the ICR healthcare leadership team, which includes Mark Klausner and Bob East (for Investor Relations), and Terri Clevenger and Michael O’Brien (for Public Relations). The transaction establishes ICR’s first official on-the-ground presence in Europe, broadening its global footprint to now include North America, Asia Pacific and UK/Europe.

Tom Ryan, Founder & CEO of ICR, said: “Consilium has long been recognized as the preeminent healthcare communications and advisory firm across Europe and our years of collaboration have allowed us to learn first-hand what makes them so unique. MJ, Amber and their team have built an incredible business, with a hard-earned reputation for deep sector expertise, highly strategic counsel and outstanding client service. Their business and culture could not align more perfectly with ICR’s and we are thrilled to advance our partnership as a single, unified team.

“We were fortunate to add the Westwicke team to ICR in 2019 and have enjoyed tremendous success since then, growing our healthcare practice nearly three-fold. Combining the Consilium and ICR Westwicke teams allows us to offer truly comprehensive global support to healthcare companies while also extending ICR’s presence into Europe,” Mr. Ryan continued.

Mary-Jane Elliott, Managing Partner at ICR Consilium, said: "Over the past 10 years we have had the great pleasure to build Consilium into Europe's leading independent strategic communications agency for the healthcare sector with the sole purpose of serving our clients globally. I am extremely proud of what we have achieved as a team and thank our clients, colleagues past and present, and fellow advisors for their ongoing trust and support.

"I am excited by our next phase of growth as part of ICR, who are backed by two leading global private equity firms – CDPQ and Investcorp, and what opportunities this offers, particularly in the US, to our clients and colleagues, including offering a broader range of capabilities. We have been joint-venture partners for almost a decade and have a complementary fit in international healthcare PR and IR advisory work. Over the years of working with ICR we have shared many clients and delivered fantastic and seamless benefits, as well as formed strong relationships with the ICR team across the US. Now is the right time to deepen that relationship, which coincides with hopefully the continued re-opening of the capital markets, and we look forward to what we can accomplish together,” Mary-Jane Elliott added.

This transaction creates one of the largest global specialist healthcare communications practices and significantly enhances ICR’s capabilities in Europe, by increasing its practice size in both revenue and headcount and broadening its service offerings. The ICR and Consilium combination will immediately provide existing and new ICR Consilium clients with access to integrated support across ICR’s entire platform of services and the combination creates exciting new growth opportunities for all team members.

Together, ICR and Consilium bring unmatched depth of expertise in healthcare advisory services across IR and strategic communications and the capabilities to support healthcare companies globally across all subsectors including biopharma, medical technology, diagnostics, healthcare services and information technology, and through all stages of growth from early-stage development, to public offerings, to mature public companies. The firm’s full range of critical strategic communication and investor relations services enable the combined team to support healthcare businesses and leaders with strategic expertise for gaining investor support, building and managing reputation, executing and communicating capital raising and other transactions, responding to crises, introducing new products, communicating regulatory developments and more.

Consilium's team of more than 45 PR and IR professionals, including former journalists, sell-side analysts, industry communications experts, and financial PR practitioners combines with ICR Westwicke’s more than 70 team members with similar professional backgrounds in healthcare. Consilium adds to ICR’s existing client base and bolsters the firm’s expertise in strategic healthcare communications and investor relations, with deep industry knowledge and an unrivalled network across the US, UK, continental Europe and Asia.

Amber Fennell, Senior Partner, ICR Consilium, added: “The combination of Consilium with ICR creates an unrivalled transatlantic strategic communications practice providing support across all aspects of healthcare corporate communications and financial transactions. ICR has an excellent brand and reputation and is one of the fastest growing communications agencies in the US. Working together we will be able to provide our combined healthcare clients with even more seamless and integrated access to a breadth of PR and IR advisory services, in London, across Europe and in the US.”

Notes to editors

About ICR

Established in 1998, ICR partners with its clients to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to approximately 1,000 clients across more than 20 industry groups. ICR’s healthcare practice operates under the ICR Westwicke brand (www.westwicke.com). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America, maintaining offices in New York, Norwalk, Boston, Baltimore, San Diego, San Jose and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR and LinkedIn.

About ICR Consilium

ICR Consilium is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. ICR Consilium's team, based in Europe and the US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision-makers and executives on critical communications programs, international media management, transactions and healthcare stakeholder challenges. ICR Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.

For more information, please see www.consilium-comms.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information:
ICR
Matt Lindberg
Tel: +1(203) 644-7028
Matthew.Linberg@icrinc.com

ICR Consilium
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
info@consilium-comms.com
www.consilium-comms.com
Follow us: @consiliumhc

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye